Johnson & Johnson Presents Positive Results from ERLEADA® Phase 2 Study for High-Risk Localized Prostate Cancer Post-Radical Prostatectomy

Johnson & Johnson has announced the results of the Phase 2 ApaRP study, unveiling promising findings regarding the effectiveness of ERLEADA® as adjuvant treatment alongside androgen deprivation therapy (ADT) in patients diagnosed with high-risk localized prostate cancer following radical prostatectomy. These results were presented today at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. The study showcased a remarkable 100% biochemical recurrence (BCR)-free rate at 24 months among patients who received the ERLEADA® and ADT regimen. Dr. Neal Shore, Steering Committee Chair and Chief Medical Officer of Surgical Oncology and Urology at Genesis Care, emphasized the significance of these findings in supporting treatment intensification for high-risk localized prostate cancer, underscoring the potential to prevent progression to metastatic disease.